Preliminary safety tolerability & efficacy results of KN046 (an anti-PD-L1/CTLA-4 bispecific antibody) in combination with Nab-paclitaxel in patients with metastatic triple-negative breast cancer (mTNBC).

被引：0
|
作者：
Xu, Binghe [1 ]
Li, Qiao [1 ]
Zhang, Qingyuan [2 ]
Zhang, Yue [2 ]
Ouyang, Quchang [3 ]
Zhang, Yang [4 ]
Liu, Qiang [5 ]
Sun, Tao [6 ]
Xu, June [7 ]
Yang, Jing [7 ]
Yang, Yue [7 ]
Luo, Xin [7 ]
Kong, Paul [7 ]
Xu, Ting [7 ]
机构：
[1] Canc Hosp Chinese Acad Med Sci, Beijing, Peoples R China
[2] Harbin Med Univ Canc Hosp, Harbin, Peoples R China
[3] Hunan Canc Hosp, Changsha, Peoples R China
[4] Liaocheng Peoples Hosp, Liaocheng, Shandong, Peoples R China
[5] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Guangzhou, Peoples R China
[6] Liaoning Canc Hosp, Dalian, Peoples R China
[7] Jiangsu Alphamab Biopharmaceut Co Ltd, Suzhou, Peoples R China
来源：
CANCER RESEARCH | 2021年 / 81卷 / 13期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1660
引用
收藏
页数：2
相关论文
共 50 条
  • [21] A phase Ill randomized trial of atezolizumab in combination with nab-paclitaxel as first line therapy for patients with metastatic triple-negative breast cancer (mTNBC)
    Emens, L.
    Adams, S.
    Loi, S.
    Schmid, P.
    Schneeweiss, A.
    Rugo, H.
    Chui, S.
    Winer, E.
    CANCER RESEARCH, 2016, 76
  • [22] Safety and efficacy of Atezolizumab in combination with nab-Paclitaxel in patients with PD-L1 positive metastatic or locally advanced triple-negative breast cancer: A pan-UK cancer centre experience
    Waterhouse, Jasmin V.
    Holdich, Alexandra
    Mina, Florentia
    Obeid, Mariam
    Joshi, Kroopa
    Barrett, Sophie
    Rajakumar, Lavarniya
    McCormick, Gemma
    Seymour, Sally
    Koliou, Panagiotis
    Sylva, Rushan
    Ayodele, Olubukola
    Gautam, Ashram
    Smith, Jenny
    McKeon, Jenny
    Strawson-Smith, Thomas
    Douglas, Rosalie
    Borley, Annabel
    Konstantis, Apostolos
    McGrath, Sophie
    CANCER RESEARCH, 2024, 84 (09)
  • [23] Preliminary efficacy and safety of KN046 (a bispecific antiPD-L1/CTLA-4) in patients with metastatic non-small cell lung cancer who previously treated with immune checkpoint inhibitor(s)
    Zhou, C.
    Xiong, A.
    Li, X.
    Fan, Y.
    Zhuang, W.
    Yu, Q.
    Xu, T.
    Xu, M.
    Liu, Q.
    Wang, N.
    Yan, X.
    ANNALS OF ONCOLOGY, 2023, 34
  • [24] KN046, a bispecific antibody against PD-L1 and CTLA-4, plus chemotherapy as first-line treatment for metastatic NSCLC: A multicenter phase 2 trial
    Zhao, Yuanyuan
    Chen, Gang
    Li, Xingya
    Wu, Jingxun
    Chang, Baoping
    Hu, Sheng
    Yang, Shujun
    Xu, Ting
    Liu, Yilan
    Wang, Ni
    Zhang, Li
    Huang, Yan
    CELL REPORTS MEDICINE, 2024, 5 (03)
  • [25] A phase Ib/II study to assess the safety and preliminary efficacy of PM8002 in combination with nab-paclitaxel in patients with triple-negative breast cancer
    Wu, Jiong
    Zhang, Jian
    Tong, Zhongsheng
    Wang, Yongsheng
    Zhang, Qingyuan
    Cheng, Qiao
    Chen, Xin
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [26] Nab-paclitaxel and atezolizumab for the treatment of PD-L1-positive, metastatic triple-negative breast cancer: review and future directions
    Kagihara, Jodi A.
    Andress, Michelle
    Diamond, Jennifer R.
    EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT, 2020, 5 (02): : 59 - 65
  • [27] Efficacy and safety of KN046, a novel bispecific antibody against PD-L1 and CTLA-4, in patients with non-small cell lung cancer who failed platinum-based chemotherapy: a phase II study
    Xiong, Anwen
    Li, Wei
    Li, Xingya
    Fan, Yun
    Ma, Zhiyong
    Fang, Jian
    Xie, Qiang
    Zhuang, Wu
    Kang, Mafei
    Wang, Jing
    Xu, Ting
    Xu, Mo
    Zhi, Lihua
    Liu, Qing
    Wang, Ni
    Zhou, Caicun
    EUROPEAN JOURNAL OF CANCER, 2023, 190
  • [28] Efficacy and safety of KN026, a bispecific anti-HER2 antibody, in combination with KN046, an anti-CTLA4/PD-L1 antibody, in patients with advanced HER2-positive nonbreast cancer: a combined analysis of a phase Ib and a phase II study
    Liu, Dan
    Gong, Jifang
    Li, Jian
    Qi, Changsong
    Niu, Zuoxing
    Liu, Bo
    Peng, Zhi
    Luo, Suxia
    Wang, Xicheng
    Wang, Yakun
    Zhao, Rusen
    Chen, Lilin
    Deng, Ting
    Li, Zhen
    Chen, Lei
    Fang, Meimei
    Yang, Hongwei
    Lu, Linzhi
    Zhang, Yanming
    Kang, Fengling
    Xu, Ting
    Zhang, Xiaotian
    Shen, Lin
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2025, 10 (01)
  • [29] Comparative effectiveness of nab-paclitaxel vs. paclitaxel m onotherapy as first-line (1L) treatment of metastatic triple-negative breast cancer (mTNBC) in US clinical practice
    Luhn, T.
    Chui, S.
    Hsieh, A.
    Yi, J.
    Mecke, A.
    Bajaj, P.
    Hasnain, W.
    Falgas, A.
    Ton, T. G. N.
    Kurian, A.
    ANNALS OF ONCOLOGY, 2018, 29 : 101 - 101
  • [30] 12-month uptake of PD-L1 testing and atezolizumab (atezo) plus nab-paclitaxel (nab-pac) treatment in metastatic triple-negative breast cancer (mTNBC) following accelerated FDA-approval in the United States.
    Emens, Leisha A.
    Craggs, Christopher
    Debiasi, Marcio
    Kent, Matthew
    Luhn, Patricia
    Hamilton, Erika Paige
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345